Valeo Pharma and Zambon Form Partnership for Parkinson's Disease Treatment Xadago® (safinamide) in Canada

MILAN, April 11, 2017 /PRNewswire/ --






- Valeo Pharma and Zambon announce a partnership in Canada which grants Valeo Pharma
exclusive rights to commercialise Zambon's Parkinson's disease product, licensed from
Newron 
- New treatment option for estimated 100,000 Canadians living with Parkinson's disease 
- Xadago(R) (safinamide) has been launched in the European Union, Switzerland, and it
has recently been approved by the U.S. Food and Drug Administration in the U.S.A. 
- Valeo Pharma to be responsible for registering and launching Xadago(R) in Canada 



Zambon S.p.A., an international pharmaceutical company strongly committed to the central nervous system (CNS) therapeutic area, and Valeo Pharma Inc., a specialty pharmaceutical company dedicated to registering and launching innovative prescription products in Canada, today announced a strategic agreement to commercialize Xadago(R) (safinamide) for the treatment of Parkinson's disease in Canada.

(Logo: http://photos.prnewswire.com/prnh/20160915/408454LOGO )



"On approval, Xadago(R) will be the first new oral treatment in almost 15 years to address this serious condition in Canada," said Steve Saviuk, President of Valeo Pharma. "We look forward to bringing this important new treatment option to more than 100,000 Canadians living with Parkinson's, and adding to our growing portfolio of prescription medications addressing major neurodegenerative diseases ."

Roberto Tascione, CEO of Zambon said, "We are very pleased to have signed our agreement with Valeo Pharma, a company with  an  excellent track record in bringing innovative products to market. Entering Canada is an important step forward in the acceptance of safinamide for patients with PD already treated with L-dopa or other therapeutic combinations."

Xadago(R) (safinamide) has been launched by Zambon in Germany, Switzerland, Spain, Italy, Belgium, Denmark, Sweden, UK, Luxembourg,  the Netherlands and Norway. Zambon S.p.A. holds the global marketing rights for safinamide with the exception of Japan/Asia. On March 21, 2017 the Food and Drug Administration (FDA) has approved the use of Xadago(R) (safinamide) for the treatment of Parkinson's disease as add-on therapy to levodopa/carbidopa

About Valeo Pharma

Valeo Pharma is a specialty pharmaceutical company dedicated to the registration and launch of innovative prescription products in Canada. With a focus on neurodegenerative diseases, kidney diseases, and hospital products, Valeo Pharma has a growing portfolio of innovative products. For more information, please visit http://www.valeopharma.com.

About Zambon  

Zambon is a leading Italian pharmaceutical and fine-chemical multinational company that has earned a strong reputation over the years for high quality products and services. Zambon is well-established in 3 therapeutic areas: respiratory, pain and women's health, and is very strongly committed to its entry into the CNS space with Xadago(R) (safinamide) for the treatment of Parkinson's disease and rare diseases with Promixin(R) in cystic fibrosis. For details please see http://www.zambongroup.com


 
For more information 

Media 
Zambon 
Luca Primavera - CCO 
Phone: +39-02-66524491 
Mobile: +39-335-7247417 
Email: luca.primavera@zambongroup.com  

Italy 
Milva Naguib 
Phone: +39-02-66524095 
Mobile: +39-3459215675 
Email: milva.naguib@zambongroup.com  

Valeo Pharma 
Steve Saviuk - President and CEO 
Phone : +1-514-693-8830 
Email : saviuk@valeopharma.com  



 



Photo:
http://photos.prnewswire.com/prnh/20160915/408454LOGO




Zambon

PR Newswire

Dit persbericht is via ANP Pers Support naar internationale (vak en online) media gestuurd. Heb je nieuws voor buitenlandse journalisten? Bekijk dan onze mogelijkheden of neem contact met ons op.

Verstuur nu éénmalig een persbericht

Verstuur persberichten en beeldmateriaal naar redacties in binnen- en buitenland. Via het ANP-net, het internationale medianetwerk van PR Newswire of met een perslijst op maat.

Direct persbericht versturen
070 - 41 41 234